MA-ADVA
ADVA (FSE: ADV) today announced that UrsaNav and ADVA have conducted an enhanced long-range navigation (eLoran) field trial using UrsaNav’s eLoran receiver and ADVA’s Oscilloquartz grandmaster clock technology. The successful demo shows that eLoran offers a robust and reliable backup for GPS and other GNSS and could be used to provide an assured position, navigation, and timing (PNT) service. The trial follows US federal executive order 13905 aimed at strengthening national resilience through PNT services, including protecting critical infrastructure such as electrical power grid and communication networks from rising cyber threats. By harnessing ADVA’s flexible OSA 5420 Series , designed with assured PNT (aPNT) technology, UrsaNav has shown that eLoran can provide a new layer of protection and significantly boost timing resilience and security.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005101/en/
“The success of this field trial demonstrates how eLoran, as part of ADVA’s assured PNT solution, can serve as a crucial backup for GPS. We have shown how our technology enables ADVA’s grandmaster clock to receive UTC timing from the eLoran system for a period of several days with the same accuracy and stability as GPS. Of course, this capability is extensible to other GNSS as well. eLoran is far less vulnerable to unintentional jamming and spoofing disruptions or intentional attacks, thereby delivering nanosecond precision with even more resilience,” said Charles Schue, CEO, UrsaNav. “By partnering with ADVA, we’ve been able to show that our eLoran receiver interoperates with the best network timing toolkit available. The OSA 5420 Series is a great product – highly efficient and easy to operate. Together with ADVA, we’re paving the way for tomorrow’s more robust assured PNT synchronization architecture.”
Across the globe, essential services and entire industries are increasingly reliant on GNSS for PNT information. But these satellite systems are inherently susceptible to interference, which could have disastrous consequences. A major disruption may result in billions of dollars of economic damage as well as a serious risk of loss of life. eLoran is one of the key technologies that could provide protection, with governments including the US exploring its potential as an alternative PNT source. UrsaNav’s latest trial harnessed the OSA 5420 Series grandmaster clock with inbuilt GNSS receiver. Timing stability from GPS was measured for several days. This was then replaced with eLoran for the same period with no loss of stability. What’s more, the test was conducted indoors where GNSS signals are not usually available, potentially extending the availability of precise UTC timing to many more environments.
“Commercially available GNSS jammers and spoofers are easy and cheap for attackers to construct. That’s part of the reason why we’re seeing a growing number of incidents across the world of blocked or misleading signals. If power utilities, enterprises, service providers and governments continue to rely on GNSS alone, it’s only a matter of time before the consequences become very serious. That’s why we’re committed to tackling GNSS vulnerabilities with advanced technologies like our ePRTC offering, cesium atomic clocks and our optical timing channel solution,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “Now that UrsaNav has demonstrated the power of our OSA 5420 Series to utilize eLoran in the event of outages, we have another very important tool to ensure the quality and availability of time-sensitive services.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .
About UrsaNav
Ursa Navigation Solutions (“UrsaNav”) is the world’s leading supplier of Low Frequency PNT solutions, with proven performance delivering the latest technology for eLoran systems, including transmission, control, monitoring, and reference site equipment. From initial concept through operational certification, UrsaNav provides every aspect of the provider or user experience, including commercial and military PNT solutions, critical infrastructure protection, and legacy system transformation. www.ursanav.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005101/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
